Australian Institute of Health and Welfare 2020. Gout . Cat. no. PHE 259. Canberra: AIHW. Viewed 23 October 2021, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare. (2020). Gout . Retrieved from https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Gout . Australian Institute of Health and Welfare, 25 August 2020, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare. Gout [Internet]. Canberra: Australian Institute of Health and Welfare, 2020 [cited 2021 Oct. 23]. Available from: https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare (AIHW) 2020, Gout , viewed 23 October 2021, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Get citations as an Endnote file:
PDF | 421Kb
Gout is a form of inflammatory arthritis that develops when an excess of uric acid in the blood leads to deposits of uric acid crystals in one or more joints, causing inflammation.
4.5% of Australians had gout in 2017–18, based on self-reported survey data. That is approximately 1.1 million people
Men are more likely to have gout than women—almost 8 in 10 (79%) people with gout are men
Gout can be managed or even prevented by long-term therapy with medications and life style changes to control hyperuricaemia and reduce levels of uric acid in the body.
Gout can be controlled with early and ongoing treatment, including:
Flares and complications can be managed by reducing risk factors for hyperuricaemia (dehydration, obesity and alcohol intake), taking urate-lowering medications to keep uric acid levels low, and managing comorbid conditions, such as high blood pressure, chronic kidney disease, diabetes and heart disease (Khanna et al. 2012).
The use of non-steroidal anti-inflammatory drugs (NSAIDs), low-dose colchicine and oral/intra-muscular/intra-articular glucocorticoids has also been found to be effective in managing acute gout (Graf et al. 2015; Richette et al. 2016).
Data from the AIHW National Hospital Morbidity Database (NHMD) show that, in 2017-18:
Source: AIHW National Hospital Morbidity Database (Data table).
The age-standardised hospitalisation rate for Australians with gout increased between 2008–09 and 2017–18 from 19 hospitalisations per 100,000 population to 27 per 100,000 population. There was a slightly larger increase for females (43%, from 7 to 10 per 100,000 population) compared with males (39%, from 33 to 46 per 100,000 population) (Figure 2).
Note: Age-standardised to the 2001 Australian population.
Graf SW, Whittle SL, Wechalekar MD, Moi JHY, Barrett C, Hill CL et al. 2015. Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. International Journal of Rheumatic Diseases 18:341–351.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al. 2012. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research 64(10):1431–1446.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J et al. 2016. 2016 updated EULAR evidence-based recommendation for the management of gout. Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2016-209707.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.